Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Endocrinology
•
Bone and Calcium Disorders
Should we aim to reduce or stop thiazides in patients with thiazide-induced hypercalcemia given its similar risk profile to untreated primary hyperparathyroidism?
Related Questions
Which fracture sites outside of the classical spine and hip are considered to be osteoporotic fractures even in the absence of a bone density diagnosis?
Does biotin interfere with the measurement of other metabolites of the Vitamin D pathway outside of the 25-hydroxy Vitamin D assay?
What treatment options would you consider for a young patient with limited mobility, low bone mass and multiple vertebral compression fractures who is on dialysis for advanced kidney disease?
Is there a role for monitoring PTH levels in patients with advanced chronic kidney disease who are receiving denosumab to assess for adynamic bone disease?
What is the optimal management of pain and loss of function due to pathologic compression fractures?
What 24 hr urine calcium cut off value do you use for recommending parathyroidectomy in patients with asymptomatic hyperparathyroidism?
Would you offer bisphosphonate therapy for infants with osteogenesis imperfecta type 11?
Do you recommend the use of albumin-adjusted calcium measurement formulas to accurately assess calcium levels?
Would you add cholecalciferol or ergocalciferol to calcitriol therapy in patients with post operative hypoparathyroidism who have low 25 OH vitamin D levels?
In patients presenting with classical findings of primary hyperparathyroidism (i.e mild hypercalcemia, high 24hr urine calcium, elevated 1,25 Vit D but normal PTH), can spontaneous normalization of calcium be explained by episodic hypersecretion of PTH?
